New hope for advanced cancer patients: experimental drug HRS-6768 enters human trials
NCT ID NCT06925581
First seen Jan 04, 2026 · Last updated May 23, 2026 · Updated 20 times
Summary
This study tests a new drug called HRS-6768 in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can help control the disease. About 84 participants will be enrolled in this early-phase trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Gaobo Hospital
RECRUITINGBeijing, Beijing Municipality, 102206, China
Contact
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact
Contact
Conditions
Explore the condition pages connected to this study.